Form 4: Allogene Therapeutics Insider Sells Shares
Insider Transaction Report
Allogene Therapeutics SVP of Finance Annie Yoshiyama sold shares to cover tax withholding obligations upon vesting of restricted stock units.
Summary
- Annie Yoshiyama, SVP of Finance at Allogene Therapeutics, Inc., reported a transaction on April 21, 2026.
- This transaction involved the sale of 9,586 shares of common stock.
- The sale was conducted to cover tax withholding obligations related to the vesting of restricted stock units.
- The sale was executed under a "sell to cover" transaction mandated by the issuer's equity incentive plan.
- The weighted average sale price was $2.31 per share, with individual transactions ranging from $2.31 to $2.33.
- Following the transaction, Yoshiyama beneficially owns 124,517 shares of common stock.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as the reported share sale is a standard procedure for covering tax obligations upon equity award vesting and does not reflect a discretionary decision to divest shares.
Positives
- The sale was not a discretionary trade but a mandated "sell to cover" to satisfy tax obligations, indicating no negative sentiment from the executive regarding the company's stock.
- The executive still holds a significant number of shares (124,517) after the transaction.
Negatives
- A total of 9,586 shares were sold, reducing the reporting person's direct holdings.
Future Outlook
No specific future outlook or guidance is provided in this Form 4 filing, as it solely reports a past transaction.
Industry Context
StockSavvy.ai notes that insider "sell to cover" transactions are common for satisfying tax liabilities upon the vesting of equity awards and are generally not indicative of a negative view on the company's prospects, especially when the executive retains a substantial number of shares.
Stakeholder Impact
- Shareholders: The transaction is a routine "sell to cover" and is unlikely to have a significant impact on the share price or overall shareholder sentiment, as it's a mechanism to satisfy tax obligations rather than a strategic sale.
Key Dates
| Date | Description |
|---|---|
| 04/21/2026 | Transaction date for the sale of common stock. |
| 03/15/2026 | Date of acquisition of 3,781 shares of common stock through an employee stock purchase program. |
| 04/23/2026 | Date of signature for the filing. |
Keywords
Allogene Therapeutics, ALLO, Form 4, Insider Transaction, Stock Sale, Tax Withholding, Restricted Stock Units, Securities and Exchange Commission
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.